Your search for smoking cessation returned 23 results

Benefits of smoking cessation medications decline over the first year.

A bacterial enzyme may be a future candidate in smoking cessation, according to a new study led by researchers at The Scripps Institute.

The data showed TNP was significantly more effective vs. no medication assisted quit attempts for males (odds ratio [OR] 1.37, 95% CI: 1.02, 1.83; P=0.03) but not for females (OR 0.96, 95% CI: 0.71, 1.31; P=0.82).

Adverse events observed among adolescent smokers in the study were comparable to those seen in adult studies.

The FDA determined the benefits of this smoking cessation therapy outweighed the potential risks.

The National Comprehensive Cancer Network (NCCN) has released Clinical Practice Guidelines in Oncology for Smoking Cessation.

At a joint meeting of the Food and Drug Administration (FDA)’s Psychopharmacologic Drugs Advisory Committee and Drug Safety Risk Management Advisory Committee, a majority vote recommended the removal of the boxed warning regarding serious neuropsychiatric adverse events from the Chantix (varenicline; Pfizer) labeling.

Varenicline did not increase the rate of cardiovascular (CV) serious adverse events, according to data from a systematic review published in the Journal of the American Heart Association.

In a first-ever prospective study evaluating lorcaserin in reducing post-cessation weight gain in overweight and obese smokers, researchers found that lorcaserin combined with varenicline minimized weight gain and increases in waist circumference.

Researchers found no significant differences in rates of smoking abstinence at 26 or 52 weeks following a 12-week treatment with a nicotine patch, varenicline, or combination nicotine replacement therapy (nicotine patch + nicotine lozenge [C-NRT]), in adults trying to quit smoking.